Slicing Through Silos: Development and Evaluation of a Hospital-based Telehealth Hepatitis C Virus Treatment Program

Overview

Journal Int J Drug Policy

Publisher Elsevier

Specialties Psychiatry
Public Health

Date 2024 Apr 9

PMID 38593518

Authors

J Babiarz

H Ryu

C Williams

Y Ham

J Rivera Sarti

X A Levander

Affiliations

Soon will be listed here.

Abstract

Background: There exist many barriers to hepatitis C virus (HCV) treatment for those with substance use disorder (SUD) or who lack access to routine medical care. A hospital-based telehealth program was developed to provide treatment opportunities for hospitalized patients living with HCV.

Methods: This single site prospective cohort study conducted from July 2022 to March 2023 aimed to measure linkage to care with an HCV clinician and initiation of HCV treatment in hospitalized patients. Patients were assessed in-person by a social worker then seen via telehealth by a clinician who prescribed either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir. Treatment was initiated with pharmacist assistance. The team conducted in-person and/or telephonic outreach during and after hospitalization. Cure was confirmed by sustained virologic response at 12 weeks (SVR12) post-treatment.

Results: A total of 25 patients were enrolled and completed telehealth visits. All patients had a history of SUD and 18 (72 %) were unstably housed. Nineteen patients (76 %) initiated treatment, and 14 (56 %) successfully completed treatment. Twelve patients (48 %) completed post-treatment labs, including two who prematurely discontinued treatment. Eleven patients (44 %) achieved confirmed cure with SVR12.

Conclusion: A hospital-based, multidisciplinary telehealth program can be an innovative care model to successfully treat HCV in a difficult-to-treat patient populations.

References

Raja S, Edwards S, Stewart J, Huynh D . Missed opportunities for hepatitis C treatment at a tertiary care hospital in South Australia. World J Hepatol. 2022; 14(8):1576-1583. PMC: 9453456. DOI: 10.4254/wjh.v14.i8.1576. View

McCrary L, Roberts K, Bowman M, Castillo B, Darling J, Dunn C . Inpatient Hepatitis C Treatment Coordination and Initiation for Patients Who Inject Drugs. J Gen Intern Med. 2023; 38(15):3428-3433. PMC: 10682347. DOI: 10.1007/s11606-023-08386-y. View

Midgard H, Malme K, Pihl C, Berg-Pedersen R, Tanum L, Klundby I . Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial. Clin Infect Dis. 2023; 78(3):582-590. PMC: 10954343. DOI: 10.1093/cid/ciad711. View

Sherbuk J, Tabackman A, McManus K, Kemp Knick T, Schexnayder J, Flickinger T . A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South. Harm Reduct J. 2020; 17(1):64. PMC: 7501689. DOI: 10.1186/s12954-020-00409-9. View

Englander H, Dobbertin K, Lind B, Nicolaidis C, Graven P, Dorfman C . Inpatient Addiction Medicine Consultation and Post-Hospital Substance Use Disorder Treatment Engagement: a Propensity-Matched Analysis. J Gen Intern Med. 2019; 34(12):2796-2803. PMC: 6854181. DOI: 10.1007/s11606-019-05251-9. View

Grebely J, Dalgard O, Conway B, Cunningham E, Bruggmann P, Hajarizadeh B . Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018; 3(3):153-161. DOI: 10.1016/S2468-1253(17)30404-1. View

Le E, Chee G, Kwan M, Cheung R . Treating the Hardest to Treat: Reframing the Hospital Admission as an Opportunity to Initiate Hepatitis C Treatment. Dig Dis Sci. 2021; 67(4):1244-1251. DOI: 10.1007/s10620-021-06941-3. View

Levander X, A Vega T, Seaman A, Korthuis P, Englander H . Utilising an access to care integrated framework to explore the perceptions of hepatitis C treatment of hospital-based interventions among people who use drugs. Int J Drug Policy. 2021; 96:103356. PMC: 8568624. DOI: 10.1016/j.drugpo.2021.103356. View

Rowan S, Wyles D . Don't Put Off Until Tomorrow What You Can Do Today: Hospital Admissions as an Opportunity to Treat Hepatitis C. Clin Infect Dis. 2023; 78(3):591-593. DOI: 10.1093/cid/ciad712. View

10.

Hajarizadeh B, Cunningham E, Reid H, Law M, Dore G, Grebely J . Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018; 3(11):754-767. DOI: 10.1016/S2468-1253(18)30304-2. View